Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Enrollment Rate Is 1.27 Patients Per Month For IPF & CC.

<< Previous

Bullboard Posts

Next >>

Post by BlaineBorgon Jul 08, 2021 1:11am

246 Views

Post# 33510533

Enrollment Rate Is 1.27 Patients Per Month For IPF & CC.

8 Months until full enrollment. 9 Months until final treatment. Fully compiled data readout... Who knows, but I suspect 1 year from now. You do the math. Christopher Moreau is pleased. I believe plenty heads should roll. BB

<< Previous

Bullboard Posts

Next >>

The Market Online’s Weekly Gold Report – Nov. 13, 2024